Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.70 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.70 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | QPCT | Q16769 | 1/20 | 0.67 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.67 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.64 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024261 | 0.90 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.88 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2529997 | 0.84 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6057476 | 0.84 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL570342 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2729830 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2393534 | 0.81 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL77025 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL7284368 | 0.81 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL707075 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | claimed |
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | claimed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | claimed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | claimed |
| CN-110799500-B | Degradable imidazolium oligomers and polymers for antimicrobial applications | 新加坡科技研究局 | 2023-10-03 | — | — | CN | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| CN-100509813-C | Hetereoaryl nitrile derivative | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1678613-A | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | CYP11B1 61/4885CYP11B2 68/4885CYP19A1 884/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP11B1 63/4885CYP11B2 60/4885CYP19A1 641/4885 |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | CYP11B1 733/4885CYP11B2 935/4885CYP19A1 168/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP11B1 63/4885CYP11B2 60/4885CYP19A1 641/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | CYP11B1 1117/4885CYP11B2 1342/4885CYP19A1 239/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP11B1 55/4885CYP11B2 52/4885CYP19A1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.